SCHEMBL987523

SCHEMBL987523

ClCc1cc(-c2ccccc2)cs1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP11B1 P15538 1/20 0.49
CYP11B2 P19099 1/20 0.49
HDAC6 Q9UBN7 1/20 0.40
ALDH1A1 P00352 6/20 0.38
NPC1 O15118 2/20 0.36
RAB9A P51151 2/20 0.36
CNR1 P21554 1/20 0.36
LMNA P02545 2/20 0.36
NPSR1 Q6W5P4 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
CYP2E1 P05181 1/20 0.35
CYP2A6 P11509 1/20 0.35
CYP2B6 P20813 1/20 0.35
GAA P10253 2/20 0.35
HPGD P15428 2/20 0.35
CYP1A2 P05177 1/20 0.34
NOTUM Q6P988 1/20 0.34
ALAD P13716 1/20 0.34
MMP12 P39900 2/20 0.34
KDM4E B2RXH2 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL988896 0.79 CYP11B1 (0.49) CYP11B1CYP11B2HDAC6ALDH1A1NPC1
SCHEMBL12531530 0.79 CYP11B1 (0.49) CYP11B1CYP11B2HDAC6ALDH1A1NPC1
SCHEMBL6375451 0.79 CYP11B1 (0.49) CYP11B1CYP11B2HDAC6ALDH1A1NPC1
SCHEMBL11824350 0.77 CYP11B1 (0.41) CYP11B1CYP11B2HDAC6ALDH1A1NPC1
SCHEMBL11261403 0.77 HDAC6 (0.43) CYP11B1CYP11B2HDAC6ALDH1A1NPC1
SCHEMBL4169939 0.76 CYP2A6 (0.42) CYP11B1CYP11B2CYP2E1CYP2A6CYP2B6
SCHEMBL2600215 0.76 ALDH1A1 (0.50) CYP11B1CYP11B2HDAC6ALDH1A1NPC1
SCHEMBL5147277 0.75 CYP11B1 (0.45) CYP11B1CYP11B2HDAC6ALDH1A1NPC1
SCHEMBL14468248 0.75 CYP11B1 (0.45) CYP11B1CYP11B2HDAC6ALDH1A1NPC1
SCHEMBL2600064 0.75 CYP11B1 (0.45) CYP11B1CYP11B2HDAC6ALDH1A1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8598355-B2 Amide compound ASTELLAS PHARMA INC. (JP) 2013-12-03 US disclosed
EP-2565191-A1 4-(Indol-7-ylcarbonylaminomethyl)cyclohexanecarboxylic acid derivatives as EP4 receptor antagonists useful for the treatment of chronic renal failure or diabetic nephropathy Astellas Pharma Inc. (JP) 2013-03-06 EP disclosed
US-20110144153-A1 AMIDE COMPOUND ASTELLAS PHARMA INC. (JP) 2011-06-16 US disclosed
US-20110144153-A1 AMIDE COMPOUND ASTELLAS PHARMA INC. (JP) 2011-06-16 US disclosed
US-20110144153-A1 AMIDE COMPOUND ASTELLAS PHARMA INC. (JP) 2011-06-16 US disclosed
CN-102026961-A Amide compound ASTELLAS PHARMA INC 2011-04-20 CN disclosed
EP-2277858-A1 AMIDE COMPOUND Astellas Pharma Inc. (JP) 2011-01-26 EP disclosed
EP-2277858-A1 AMIDE COMPOUND Astellas Pharma Inc. (JP) 2011-01-26 EP disclosed
WO-2009139373-A1 AMIDE COMPOUND アステラス製薬株式会社 (JP) 2009-11-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110144153-A1 AMIDE COMPOUND PTGER4, PTGER1, PTGER2 CYP11B1 3162/4885CYP11B2 2632/4885HDAC6 1766/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.